Skip to main content
Erschienen in: Supportive Care in Cancer 3/2012

01.03.2012 | Original Article

The relationship between numbness, tingling, and shooting/burning pain in patients with chemotherapy-induced peripheral neuropathy (CIPN) as measured by the EORTC QLQ-CIPN20 instrument, N06CA

verfasst von: Sherry L. Wolf, Debra L. Barton, Rui Qin, Edward J. Wos, Jeff A. Sloan, Heshan Liu, Neil K. Aaronson, Daniel V. Satele, Bassam I. Mattar, Nathan B. Green, Charles L. Loprinzi

Erschienen in: Supportive Care in Cancer | Ausgabe 3/2012

Einloggen, um Zugang zu erhalten

Abstract

Background

Chemotherapy-induced peripheral neuropathy (CIPN) is characterized by numbness, tingling, and shooting/burning pain. This analysis was performed to describe the relationship between numbness, tingling, and shooting/burning pain in patients with CIPN, as reported using the EORTC QLQ-CIPN20 (CIPN20).

Methods

Baseline CIPN20 data were provided for all patients on a prospective trial designed to treat patients with bothersome CIPN. Baseline frequencies for the items on the CIPN20 are primarily described by descriptive statistics and histograms, with correlational analyses between individual items.

Results

A majority of the 199 patients accrued to this study reported “quite a bit” to “very much” numbness (57%) or tingling (63%) in the hands compared to “a little” or “not at all” (numbness (43%), tingling (38%)). Fewer patients reported “quite a bit” to “very much” shooting/burning pain in the hands (18%). Numbness and tingling in the hands were highly correlated (r = 0.69), while neither were highly correlated with shooting/burning pain. Similar results were observed in the feet. More severe ratings for tingling and shooting/burning pain were ascribed to the lower extremities, as opposed to the upper extremities.

Conclusions

In patients with CIPN, severe sensory neuropathy symptoms (numbness, tingling) commonly exist without severe neuropathic pain symptoms (shooting/burning pain), while the reverse is not common. Symptoms in the feet should be evaluated distinctly from those in the hands as the experience of symptoms is not identical, for individual patients, in upper versus lower extremities.
Literatur
1.
Zurück zum Zitat Cavaletti G et al (1995) Peripheral neurotoxicity of taxol in patients previously treated with cisplatin. Cancer 75(5):1141–1150PubMedCrossRef Cavaletti G et al (1995) Peripheral neurotoxicity of taxol in patients previously treated with cisplatin. Cancer 75(5):1141–1150PubMedCrossRef
2.
Zurück zum Zitat Cavaletti G et al (1998) Carboplatin toxic effects on the peripheral nervous system of the rat. Ann Oncol 9(4):443–447PubMedCrossRef Cavaletti G et al (1998) Carboplatin toxic effects on the peripheral nervous system of the rat. Ann Oncol 9(4):443–447PubMedCrossRef
3.
Zurück zum Zitat Ocean AJ, Vahdat LT (2004) Chemotherapy-induced peripheral neuropathy: pathogenesis and emerging therapies. Support Care Cancer 12(9):619–625PubMed Ocean AJ, Vahdat LT (2004) Chemotherapy-induced peripheral neuropathy: pathogenesis and emerging therapies. Support Care Cancer 12(9):619–625PubMed
4.
Zurück zum Zitat Pace A et al (1997) Paclitaxel neurotoxicity: clinical and neurophysiological study of 23 patients. Ital J Neurol Sci 18(2):73–79PubMedCrossRef Pace A et al (1997) Paclitaxel neurotoxicity: clinical and neurophysiological study of 23 patients. Ital J Neurol Sci 18(2):73–79PubMedCrossRef
5.
Zurück zum Zitat Rowinsky EK et al (1993) Neurotoxicity of taxol. J Natl Cancer Inst Monogr 15:107–115PubMed Rowinsky EK et al (1993) Neurotoxicity of taxol. J Natl Cancer Inst Monogr 15:107–115PubMed
6.
Zurück zum Zitat Verstappen CC et al (2003) Neurotoxic complications of chemotherapy in patients with cancer: clinical signs and optimal management. Drugs 63(15):1549–1563PubMedCrossRef Verstappen CC et al (2003) Neurotoxic complications of chemotherapy in patients with cancer: clinical signs and optimal management. Drugs 63(15):1549–1563PubMedCrossRef
8.
Zurück zum Zitat Windebank AJ, Grisold W (2008) Chemotherapy-induced neuropathy. J Peripher Nerv Syst 13(1):27–46PubMedCrossRef Windebank AJ, Grisold W (2008) Chemotherapy-induced neuropathy. J Peripher Nerv Syst 13(1):27–46PubMedCrossRef
9.
Zurück zum Zitat LoMonaco M et al (1992) Cisplatin neuropathy: clinical course and neurophysiological findings. J Neurol 239(4):199–204PubMedCrossRef LoMonaco M et al (1992) Cisplatin neuropathy: clinical course and neurophysiological findings. J Neurol 239(4):199–204PubMedCrossRef
10.
Zurück zum Zitat Nikcevich DA et al (2008) A phase III randomized, placebo-controlled, double-blind study of intravenous calcium/magnesium to prevent oxaliplatin-induced sensory neurotoxicity, N04C7. J Clin Oncol 26(15):4009 Nikcevich DA et al (2008) A phase III randomized, placebo-controlled, double-blind study of intravenous calcium/magnesium to prevent oxaliplatin-induced sensory neurotoxicity, N04C7. J Clin Oncol 26(15):4009
11.
Zurück zum Zitat Postma TJ et al (2005) The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20. Eur J Cancer 41(8):1135–1139PubMedCrossRef Postma TJ et al (2005) The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20. Eur J Cancer 41(8):1135–1139PubMedCrossRef
12.
Zurück zum Zitat Binder A et al (2007) Pain in oxaliplatin-induced neuropathy—sensitisation in the peripheral and central nociceptive system. Eur J Cancer 43(18):2658–2663PubMedCrossRef Binder A et al (2007) Pain in oxaliplatin-induced neuropathy—sensitisation in the peripheral and central nociceptive system. Eur J Cancer 43(18):2658–2663PubMedCrossRef
13.
Zurück zum Zitat Dougherty PM et al (2004) Taxol-induced sensory disturbance is characterized by preferential impairment of myelinated fiber function in cancer patients. Pain 109(1–2):132–142PubMedCrossRef Dougherty PM et al (2004) Taxol-induced sensory disturbance is characterized by preferential impairment of myelinated fiber function in cancer patients. Pain 109(1–2):132–142PubMedCrossRef
14.
Zurück zum Zitat Cata JP et al (2006) Clinical and experimental findings in humans and animals with chemotherapy-induced peripheral neuropathy. Minerva Anestesiol 72(3):151–169PubMed Cata JP et al (2006) Clinical and experimental findings in humans and animals with chemotherapy-induced peripheral neuropathy. Minerva Anestesiol 72(3):151–169PubMed
15.
Zurück zum Zitat Paice JA (2009) Clinical challenges: chemotherapy-induced peripheral neuropathy. Semin Oncol Nurs 25(2 Suppl 1):S8–S19PubMedCrossRef Paice JA (2009) Clinical challenges: chemotherapy-induced peripheral neuropathy. Semin Oncol Nurs 25(2 Suppl 1):S8–S19PubMedCrossRef
16.
Zurück zum Zitat NCI Cancer Therapy Evaluation Program (2006) Common Terminology Criteria for Adverse Events version 3.0. National Cancer Institute, Bethesda NCI Cancer Therapy Evaluation Program (2006) Common Terminology Criteria for Adverse Events version 3.0. National Cancer Institute, Bethesda
17.
Zurück zum Zitat Serlin RC et al (1995) When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function. Pain 61(2):277–284PubMedCrossRef Serlin RC et al (1995) When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function. Pain 61(2):277–284PubMedCrossRef
18.
Zurück zum Zitat Barton D et al. (2011) A double blind, placebo controlled trial of a topical treatment for chemotherapy induced peripheral neuropathy: NCCTG trial N06CA. Supportive Care Cancer. 2010 May 25. [Epub ahead of print] Barton D et al. (2011) A double blind, placebo controlled trial of a topical treatment for chemotherapy induced peripheral neuropathy: NCCTG trial N06CA. Supportive Care Cancer. 2010 May 25. [Epub ahead of print]
19.
Zurück zum Zitat Nunnally J, Bernstein I (1994) Psychometric theory, 3rd edn. McGraw-Hill, New York Nunnally J, Bernstein I (1994) Psychometric theory, 3rd edn. McGraw-Hill, New York
20.
Zurück zum Zitat Liu H et al (2008) Comparing and validating simple measures of patient-reported peripheral neuropathy (PRPN) for NCCTG Clinical Trials: a pooled analysis of 2,440 patients (pts). J Clin Oncol 26:9534 Liu H et al (2008) Comparing and validating simple measures of patient-reported peripheral neuropathy (PRPN) for NCCTG Clinical Trials: a pooled analysis of 2,440 patients (pts). J Clin Oncol 26:9534
21.
22.
Zurück zum Zitat Wilkes G (2007) Peripheral neuropathy related to chemotherapy. Semin Oncol Nurs 23(3):162–173PubMedCrossRef Wilkes G (2007) Peripheral neuropathy related to chemotherapy. Semin Oncol Nurs 23(3):162–173PubMedCrossRef
Metadaten
Titel
The relationship between numbness, tingling, and shooting/burning pain in patients with chemotherapy-induced peripheral neuropathy (CIPN) as measured by the EORTC QLQ-CIPN20 instrument, N06CA
verfasst von
Sherry L. Wolf
Debra L. Barton
Rui Qin
Edward J. Wos
Jeff A. Sloan
Heshan Liu
Neil K. Aaronson
Daniel V. Satele
Bassam I. Mattar
Nathan B. Green
Charles L. Loprinzi
Publikationsdatum
01.03.2012
Verlag
Springer-Verlag
Erschienen in
Supportive Care in Cancer / Ausgabe 3/2012
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-011-1141-9

Weitere Artikel der Ausgabe 3/2012

Supportive Care in Cancer 3/2012 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.